Menu
← Oncology Approval Tracker
FDA DECISION ·
Kisqali / Kisqali Femara Co-Pack
ribociclib with endocrine therapy · Novartis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds men to the labeled HR-positive, HER2-negative advanced or metastatic breast cancer populations. Regimens include ribociclib with an aromatase inhibitor as initial endocrine therapy, or with fulvestrant initially or after progression on endocrine therapy in men or postmenopausal women. The co-pack contains letrozole.
LAMPGEN ANALYSIS
Why it matters
The label expands CDK4/6-based endocrine treatment eligibility to men with the specified subtype.
What research teams should watch
Capture sex, receptor results, endocrine history and the selected regimen when applying the revised label.
PRIMARY RECORDS